Previous 10 | Next 10 |
Sigilon Therapeutics has filed to raise capital via an IPO. The firm is developing treatments for blood disorders and other diseases. SGTX has produced intriguing preclinical study results for its lead candidate for the treatment of Hemophilia A. For further details see: ...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this event. For further details see: Amicus Therapeutics (FOLD) Presents At Credit Suisse 29th Annual Virtual Healthcare Conference - Slideshow
Image source: The Motley Fool. Amicus Therapeutics Inc (NASDAQ: FOLD) Q3 2020 Earnings Call Nov 6, 2020 , 8:30 p.m. ET Operator Continue reading For further details see: Amicus Therapeutics Inc (FOLD) Q3 2020 Earnings Call Transcript
Amicus Therapeutics, Inc. (FOLD) Q3 2020 Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Andrew Faughnan - Director of IR John Crowley - Chairman & CEO Bradley Campbell - President & COO Mitch Goldman - SVP of Clinical Research Jeff Castelli - Chief Develo...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Amicus Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Amicus Therapeutics (FOLD): Q3 GAAP EPS of -$0.25 misses by $0.04.Revenue of $67.44M (+38.3% Y/Y) beats by $2.56M.Shares -0.73% PM.Press Release For further details see: Amicus Therapeutics EPS misses by $0.04, beats on revenue
Galafold 3Q20 Revenue of $67.4 Million, On-Track to Achieve Revenue Guidance of $250M-$260M AT-GAA Phase 3 PROPEL Study Readout in 1Q21 and Rolling BLA Submission to Begin in 4Q20 Positive CLN6 Batten Disease Gene Therapy Data Presented in October ...
CRANBURY, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020 at 8:00 a.m. ET. A l...
CRANBURY, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2020....
Amicus Therapeutics (FOLD), Plug Power (PLUG), and Fortress Transportation and Infrastructure Investors (FTAI) are trading at affordable prices even despite the market’s strong action off the March lows. These stocks have the necessary fundamentals to deliver solid returns while having...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....